Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study

The safety and efficacy of tocilizumab for the treatment of severe respiratory symptoms due to COVID-19 remain uncertain, in particular among solid organ transplant (SOT) recipients. Thus, we evaluated the clinical characteristics and outcomes of 29 hospitalized SOT recipients who received tocilizum...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Transplant
Autors principals: Pereira, Marcus R., Aversa, Meghan M., Farr, Maryjane A., Miko, Benjamin A., Aaron, Justin G., Mohan, Sumit, Cohen, David J., Husain, Syed A., Ratner, Lloyd E., Arcasoy, Selim, Uriel, Nir, Zheng, Elizabeth X., Fox, Alyson N., Tsapepas, Demetra S., Emond, Jean C., Verna, Elizabeth C.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. 2020
Matèries:
Brief Communication
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7537322/
https://ncbi.nlm.nih.gov/pubmed/32946668
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajt.16314
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars